Iyengar Srinivas, Rabbani LeRoy E
Center for Interventional Vascular Therapy, Division of Cardiology, Columbia University Medical Center, New York, NY, USA.
J Thromb Thrombolysis. 2009 Apr;27(3):300-6. doi: 10.1007/s11239-008-0221-2. Epub 2008 Apr 9.
The adenosine diphosphate (ADP) receptor antagonists, specifically the class of thienopyridines, have emerged as potent tools in the clinician's arsenal for the treatment of athero-thrombotic disease over the last two decades. Though these medications have been clearly demonstrated to have significant platelet-inhibiting effects, their potential positive impact on other systemic processes has been less well elucidated. Recent evidence points to a number of potential pleiotropic effects of these agents, most notably in the attenuation of several pro-inflammatory pathways, which may be independent of their anti-platelet-aggregating effect. Additionally, several new ADP receptor antagonists are under investigation; it remains to be seen if these agents possess any additional beneficial pleiotropic properties as well.
在过去二十年中，二磷酸腺苷（ADP）受体拮抗剂，特别是噻吩吡啶类药物，已成为临床医生治疗动脉粥样硬化血栓形成疾病的有力工具。尽管这些药物已被明确证明具有显著的血小板抑制作用，但其对其他全身过程的潜在积极影响尚未得到充分阐明。最近的证据表明这些药物具有多种潜在的多效性作用，最显著的是在减弱几种促炎途径方面，这可能与其抗血小板聚集作用无关。此外，几种新型ADP受体拮抗剂正在研究中；这些药物是否也具有任何额外的有益多效性特性还有待观察。
